HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) CME: Take the course for this article: Volume 63, Number 8, October 26, 2004 Correspondence: Submit a response Alert me when this article is cited Alert me when Correspondence are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Wheless, J. W. Articles by Pellock, J. M. Search for Related Content PubMed PubMed Citation Articles by Wheless, J. W. Articles by Pellock, J. M. Related Collections All Epilepsy/Seizures Antiepileptic drugs Related Article

Rapid infusion with valproate sodium is well tolerated in patients with epilepsy

From the Department of Neurology and Pediatrics (Dr. Wheless), University of Texas Health Science Center, Houston; Department of Neurology and Pediatrics (Drs. Pellock and Morton), Medical College of Virginia, Virginia Commonwealth University, Richmond, VA; Department of Neurology (Dr. Vazquez), New York University Medical Center, NY; Department of Neurological Sciences (Dr. Kanner), Rush University Medical Center, Chicago, IL; Department of Neurology (Dr. Ramsay), University of Miami, FL.

Address correspondence and reprint requests to Dr. John M. Pellock, Department of Neurology, Medical College of Virginia, 307 College Street, Richmond, VA 23219; e-mail: jpellock{at}hsc.vcu.edu

Many IV antiepileptic drugs administered in emergency situations to patients with prolonged seizures have serious adverse effects. For this reason, the authors conducted a multicenter, open-label, prospective, dose-escalation study of IV valproate sodium administered to patients with epilepsy at rates of infusion of up to 6 mg/kg/minute and doses of up to 30 mg/kg. Valproate sodium had no clinically significant negative effects on blood pressure and pulse rate and caused only mild-to-moderate, reversible adverse events.

Received December 17, 2003. Accepted in final form June 10, 2004.

J.W.W. has received research support and honoraria from Abbott Laboratories. J.M.P. has received research support and honoraria from and has served as a consultant and on the speaker’s bureaus for Abbott Laboratories. R.E.R. has received research support from and has served as a consultant for Abbott Laboratories.

Related Article

October 26 Highlights
Neurology 2004 63: 1346-1347. [Full Text] [PDF]

This article has been cited by other articles:

				J. W. Wheless, D. Clarke, C. A. Hovinga, M. Ellis, M. Durmeier, A. McGregor, and F. Perkins Rapid Infusion of a Loading Dose of Intravenous Levetiracetam With Minimal Dilution: A Safety Study J Child Neurol, August 1, 2009; 24(8): 946 - 951. [Abstract] [PDF]

				V. Mehta, P. Singhi, and S. Singhi Intravenous Sodium Valproate Versus Diazepam Infusion for the Control of Refractory Status Epilepticus in Children: A Randomized Controlled Trial J Child Neurol, October 1, 2007; 22(10): 1191 - 1197. [Abstract] [PDF]

				S. Beyenburg, C. Back, N. Diederich, M. Lewis, and M. Reuber Is valproate encephalopathy under-recognised in older people? A case series Age Ageing, May 1, 2007; 36(3): 344 - 346. [Abstract] [Full Text] [PDF]

				S. S. Chung, N. C. Wang, and D. M. Treiman Comparative Efficacy and Safety of Antiepileptic Drugs for the Treatment of Status Epilepticus Journal of Pharmacy Practice, April 1, 2007; 20(2): 137 - 146. [Abstract] [PDF]